Drug Giant Eli Lilly Shuns Subsidised Medication Listing, Citing Unfair Price

Eli Lilly refused to list its diabetes drug Mounjaro on Australia's PBS because the government's offered price was too low. This affects 450,000 Australians with Type 2 diabetes.

#EliLilly, #Mounjaro, #DiabetesAustralia, #PBS, #DrugPricing

https://newsletter.tf/eli-lilly-refuses-mounjaro-pbs-listing-australia/

Eli Lilly's decision means Mounjaro won't be subsidised on Australia's PBS. This affects around 450,000 people with Type 2 diabetes who might not get cheaper access to the drug.

#EliLilly, #Mounjaro, #DiabetesAustralia, #PBS, #DrugPricing
https://newsletter.tf/eli-lilly-refuses-mounjaro-pbs-listing-australia/

Eli Lilly Won't List Mounjaro on Australia's PBS Due to Low Price

Eli Lilly refused to list its diabetes drug Mounjaro on Australia's PBS because the government's offered price was too low. This affects 450,000 Australians with Type 2 diabetes.

NewsletterTF

Toddler Captures Oval Office Spotlight Amid Policy Discussions

A 2-year-old boy's hearing was restored by a Regeneron drug, overshadowing talks on drug costs in the Oval Office on April 23, 2026.

#HearingRestoration, #DrugPricing, #OvalOffice, #Regeneron, #TravisSmith

https://newsletter.tf/toddler-hearing-restored-drug-price-talks/

A young child's personal medical success story became the main news, even as the government discussed lowering drug prices.

#HearingRestoration, #DrugPricing, #OvalOffice, #Regeneron, #TravisSmith
https://newsletter.tf/toddler-hearing-restored-drug-price-talks/

Toddler's Hearing Restoration Steals Focus from Drug Prices

A 2-year-old boy's hearing was restored by a Regeneron drug, overshadowing talks on drug costs in the Oval Office on April 23, 2026.

NewsletterTF

Trump secures drug pricing agreements with all 17 targeted pharmaceutical manufacturers under his most favored nation policy, though Democrats question if consumers will see real savings.

https://worldbriefly.news/trump-completes-drug-pricing-deals-with-all-17-targeted-manufacturers-including-

#DrugPricing #Healthcare #Trump

Vas Narasimhan, Novartis CEO, warns of serious long-term consequences from President Trump's most favored nation drug pricing policy. The real impact on drugmakers and patients is expected within 18 months as U.S. prices link to lower foreign rates. This policy is set to stay, urging nations to rethink drug pricing strategies. Learn more about its implications. https://www.cnbc.com/2026/04/28/novartis-ceo-stock-earnings-mfn-trump-drug-pricing-policy.html #DrugPricing #Novartis #HealthcarePolicy
Annika Kim Constantino reports: A historic agreement slashes drug prices! Regeneron will offer its FDA-approved hearing-loss gene therapy, Otarmeni, free to eligible U.S. patients. This move, made with President Trump, is a significant step for families needing alternatives to cochlear implants. Learn more about this monumental healthcare development.
https://www.cnbc.com/2026/04/23/regeneron-inks-drug-pricing-deal-with-trump-will-offer-hearing-loss-therapy-for-free.html #DrugPricing #Healthcare #GeneTherapy

340B Drug Pricing Program Under Scrutiny: Examining Program Goals and Real-World Effects

The 340B program helps hospitals get cheaper drugs for poor patients. Learn how it works and why it's being discussed.

#340BProgram, #DrugPricing, #HealthcareCosts, #PatientAccess, #HospitalSavings

https://newsletter.tf/340b-drug-program-how-hospitals-get-cheaper-drugs-for-poor-patients/

The 340B program helps hospitals get drugs for low-income patients at lower prices. This program is now being looked at closely by the government.

#340BProgram, #DrugPricing, #HealthcareCosts, #PatientAccess, #HospitalSavings

https://newsletter.tf/340b-drug-program-how-hospitals-get-cheaper-drugs-for-poor-patients/

340B Drug Program Changes: How Hospitals Get Cheaper Drugs for Poor Patients

The 340B program helps hospitals get cheaper drugs for poor patients. Learn how it works and why it's being discussed.